Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid pressure from rival Eli Lilly.Read More

You might also be interested in reading Stablecoin Storm — Gemini’s GUSD Shrinks 93% Amidst Market Turbulence.